THERABOT · Therapeutic Bacteria Biohybrids For Oncology Treatment

Lines connect the coordinator with its partners.

Project objective

THERABOT pioneers a groundbreaking approach in the fight against cancer through the development of engineered biohybrid agents, iBots. These iBots represent a significant leap in bacterial cancer therapy (BCT), combining synthetic biology and nanotechnology to encapsulate therapeutic bacteria with protective polymeric coatings. This encapsulation aims to enhance the delivery and efficacy of bacteria to colonize tumor tissue, drastically reducing the adverse immune responses and systemic toxicity associated with traditional BCT. THERABOT's innovative strategy focuses on colorectal cancer, employing a multifaceted approach that includes the design of advanced intelligent biohybrids by programming iBots for targeted therapeutic action, and validating their effectiveness in vivo. Central to THERABOT's mission is its interdisciplinary and international consortium, comprising 12 members from 10 leading academic institutions and 2 SMEs across Europe (France, Spain and Sweden) and from non-EU countries (Japan, Argentina, Chile, Brazil and Thailand). This collaboration fosters a unique integration of diverse scientific disciplines, including bioengineering, immunology, material science and oncology, promoting the exchange of knowledge, techniques, and cultural perspectives, which is pivotal for addressing the complex challenges of developing a new cancer therapy. THERABOT not only emphasizes the scientific innovation but also prioritizes the training and career development of seconded staff, enhancing their research competencies and preparing them for future challenges in diverse fields. THERABOT's focus on developing accessible and patient-friendly cancer treatments, underscores its alignment with EU priorities in health and innovation. By redefining cancer treatment paradigms towards more precise, effective, and personalized approaches, our project aspires to have a lasting impact on society, improving patient outcomes, and contributing to the global fight against cancer.

Original text from CORDIS.

Participants

• INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE · ParisCoordinatorFrance
• A5 SCIENCE · AIX EN PROVENCEFrance
• ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOMATERIALES- CIC biomaGUNE · San SebastianSpain
• CHULALONGKORN UNIVERSITY · BangkokThailand
• CONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS Y TECNICAS (CONICET) · Buenos AiresArgentina
• INDICATE SOLUTIONS, SL · DONOSTIA/SAN SEBASTIANSpain
• NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY · TokyoJapan
• NATIONAL UNIVERSITY CORPORATION THE UNIVERSITY OF TOKYO · TOKYOJapan
• PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE · SantiagoChile
• UNIVERSIDAD NACIONAL DEL LITORAL · Santa FeArgentina
• UNIVERSIDAD NACIONAL DEL SUR · Bahia BlancaArgentina
• UNIVERSIDAD TECNOLOGICA METROPOLITANA · SantiagoChile
• UPPSALA UNIVERSITET · UppsalaSweden
• Universidade Federal de Juiz de Fora · Juiz De ForaBrazil

Links

• View on CORDIS
• DOI: 10.3030/101182953
• https://ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e51f9b1ea0&appId=PPGMS